BBNX Beta Bionics, Inc.
Healthcare$11.72-0.85%ClosedMarket Cap: $522.3M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
1.94
P/S
4.78
EV/EBITDA
-7.25
DCF Value
$-156.71
FCF Yield
-11.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
57.2%
Operating Margin
-70.1%
Net Margin
-60.3%
ROE
-23.0%
ROA
-21.8%
ROIC
-27.3%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $27.6M | 59.5% | $-24.3M | $-21.9M | $— | — |
| Q4 null | $32.1M | 59.0% | $-16.1M | $-13.5M | $— | — |
| FY null | $100.3M | 55.4% | $-71.7M | $-73.2M | $— | — |
| Q3 null | $27.3M | 55.5% | $-17.0M | $-14.2M | $— | — |
| Q2 null | $23.2M | 53.8% | $-19.9M | $-16.9M | $— | — |
| Q1 null | $17.6M | 50.9% | $-18.6M | $-28.7M | $— | — |
| Q4 null | $20.4M | 57.2% | $-13.0M | $-18.1M | $— | — |
| FY null | $65.1M | 55.1% | $-45.3M | $-54.8M | $— | — |
| Q3 null | $16.7M | 53.4% | $-11.0M | $-9.7M | $— | — |
| Q2 null | $15.0M | 53.7% | $-11.8M | $-14.5M | $— | — |
| Q1 null | $12.9M | 55.7% | $-9.5M | $-12.4M | $— | — |
| Q4 2023 | $8.3M | 60.6% | $-8.4M | $-18.8M | $-3.13 | — |